Author:
Makhlouf A,Kshirsagar A,Niederberger C
Publisher
Springer Science and Business Media LLC
Reference33 articles.
1. Lin CS, Xin ZC, Lin G, Lue TF . Phosphodiesterases as therapeutic targets. Urology 2003; 61: 685–691.
2. Saenz de Tejada I, Angulo Frutos J, Gaudo M, Florio V . Comparative selectivity profiles of Tadalafil, Sildenafil and Vardenafil using an in vitro phosphodiesterase activity assay. Int J Impot Res 2002; 14 (Suppl 4): S20–S32.
3. Gbekor E, Bethel S, Fawcett L, Mount N, Phillips S . Selectivity of sildenafil and other phosphodiesterase type 5 (PDE5) inhibitors against all human phosphodiesterase families. Eur Urol Suppl 2002; 1 (Suppl 1): 63.
4. Maw GN, Allerton CM, Gbekor E, Million WA . Design, synthesis and biological activity of beta-carboline-based type-5 phosphodiesterase inhibitors. Bioorg Med Chem Lett 2003; 13: 1425–1428.
5. Weeks JL, Zoraghi R, Beasley A, Sekhar KR, Francis SH, Corbin JD . High biochemical selectivity of tadalafil, sildenafil and vardenafil for human phosphodiesterase 5A1 (PDE5) over PDE11A4 suggests the absence of PDE11A4 cross-reaction in patients. Int J Impot Res 2005; 17: 5–9.
Cited by
50 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献